{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:58:21Z","timestamp":1790715501776,"version":"4.1.0"},"reference-count":37,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have transformed cancer care but impose a growing financial burden on Medicare. We characterized Medicare Part B spending and utilization patterns for ICIs from 2018 to 2022 to quantify expenditure trends and identify key cost drivers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of the Centers for Medicare &amp; Medicaid Services (CMS) Medicare Part B Spending by Drug public summary files (aggregated Healthcare Common Procedure Coding System [HCPCS] drug-year data) from 2018 through 2022. For eight ICIs, we extracted total gross program spending, total dosage units (HCPCS billing units), and unique beneficiaries and calculated average spending per dosage unit, average spending per beneficiary, and growth metrics over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>In 2022, total Medicare Part B spending across the eight ICIs was approximately $8.49 billion US dollars (USD). Pembrolizumab accounted for the largest spending ($4.94 billion USD) and beneficiary utilization (67,022 beneficiaries), followed by nivolumab ($1.85 billion USD; 26,957 beneficiaries). Average spending per beneficiary in 2022 (the primary cost metric, capturing dose frequency and treatment duration) ranged from $53,508 USD (durvalumab) to $80,705 USD (atezolizumab). Average spending per dosage unit varied widely as a secondary pricing measure, from $27.02 USD (cemiplimab) to $216.09 USD (dostarlimab).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Medicare Part B spending on ICIs is highly concentrated among pembrolizumab and nivolumab, and is driven primarily by beneficiary volume, with substantial heterogeneity in per-beneficiary spending across agents. As indications and utilization continue to expand, these therapies' fiscal impact warrants ongoing evaluation to inform Medicare payment policy and value-based oncology care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-26-00461","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:59:12Z","timestamp":1790711952000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary Patterns of Medicare Part B Spending on Immune Checkpoint Inhibitors (2018-2022)"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4572-8957","authenticated-orcid":true,"given":"Vidit","family":"Majmundar","sequence":"first","affiliation":[{"name":"Department of Cardiology, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4527-8120","authenticated-orcid":true,"given":"Charmi","family":"Bhanushali","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharanya","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3115-5286","authenticated-orcid":true,"given":"Pragya","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Baptist Hospital of Southeast Texas, Beaumont, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7473-3131","authenticated-orcid":true,"given":"Vidhi","family":"Bhanushali","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Switzer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Saint Vincent Hospital, Worcester, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_3_5_5_2","volume-title":"Medicare Part B Drugs: Trends in Spending and Utilization, 2008\u20132021","author":"Nguyen X","year":"2023","unstructured":"Nguyen X, Olsen TA, Sheingold SH, et al: Medicare Part B Drugs: Trends in Spending and Utilization, 2008\u20132021. Washington, DC, ASPE, 2023"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.21468"},{"key":"e_1_3_5_7_2","volume-title":"Medicare Part B Spending by Drug Data Dictionary","year":"2025","unstructured":"Medicare Part B Spending by Drug Data Dictionary. 2025. https:\/\/data.cms.gov\/summary-statistics-on-use-and-payments\/medicare-medicaid-spending-by-drug\/medicare-part-b-spending-by-drug"},{"key":"e_1_3_5_8_2","volume-title":"Medicare Part B Spending by Drug: Methodology","author":"Centers for Medicare & Medicaid Services","year":"2025","unstructured":"Centers for Medicare & Medicaid Services: Medicare Part B Spending by Drug: Methodology, 2025. https:\/\/data.cms.gov\/resources\/medicare-part-b-spending-by-drug-methodology"},{"key":"e_1_3_5_9_2","volume-title":"Medicare Part B Spending by Drug Data Dictionary","year":"2025","unstructured":"Medicare Part B Spending by Drug Data Dictionary. 2025. https:\/\/data.cms.gov\/resources\/medicare-part-b-spending-by-drug-data-dictionary"},{"key":"e_1_3_5_10_2","volume-title":"SEER-Medicare Linked Database","author":"National Cancer Institute","unstructured":"National Cancer Institute: SEER-Medicare Linked Database. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/"},{"key":"e_1_3_5_11_2","volume-title":"Consumer Price Index for All Urban Consumers (CPI-U)","author":"US Bureau of Labor Statistics","unstructured":"US Bureau of Labor Statistics: Consumer Price Index for All Urban Consumers (CPI-U). https:\/\/www.bls.gov\/news.release\/cpi.t01.htm"},{"key":"e_1_3_5_12_2","volume-title":"Medicare Part B Drug Spending Dashboard","author":"Centers for Medicare & Medicaid Services","year":"2023","unstructured":"Centers for Medicare & Medicaid Services: Medicare Part B Drug Spending Dashboard, 2023. https:\/\/data.cms.gov\/tools\/medicare-part-b-drug-spending-dashboard"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.10.017"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2043634"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0082"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0341154"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.573852"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(18)33792-8"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2219448"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-4294"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01157-3"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1046424"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.09.014"},{"key":"e_1_3_5_24_2","volume-title":"Combination with Carboplatin and Paclitaxel: CADTH Reimbursement Review","year":"2024","unstructured":"Dostarlimab (Jemperli): Therapeutic area: Endometrial cancer, in Combination with Carboplatin and Paclitaxel: CADTH Reimbursement Review, Ottawa, Canada, Canadian Agency for Drugs and Technologies in Health, 2024"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1391896"},{"key":"e_1_3_5_26_2","first-page":"e1399","article-title":"A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan","volume":"4","author":"Chang W","year":"2021","unstructured":"Chang W, Lin AY, Hsu JC, et al: A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan. Cancer Rep 4:e1399, 2021","journal-title":"Cancer Rep"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2022.10.001"},{"key":"e_1_3_5_28_2","volume-title":"Nivolumab and Relatlimab (Opdualag): CADTH Reimbursement Review: Therapeutic Area: Unresectable or Metastatic Melanoma","year":"2024","unstructured":"Nivolumab and Relatlimab (Opdualag): CADTH Reimbursement Review: Therapeutic Area: Unresectable or Metastatic Melanoma. Ottawa, Canada, Canadian agency for Drugs and Technologies in Health, 2024"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1962002"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0152"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1521416"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.0033"},{"key":"e_1_3_5_34_2","volume-title":"CMS Selects the Drugs for the Third Cycle of Drug Price Negotiations","author":"Centers for Medicare & Medicaid Services","year":"2026","unstructured":"Centers for Medicare & Medicaid Services: CMS Selects the Drugs for the Third Cycle of Drug Price Negotiations, 2026. https:\/\/www.cms.gov\/newsroom\/press-releases"},{"key":"e_1_3_5_35_2","volume-title":"Medicare Drug Price Negotiation Program: Medicare Prices Negotiated for 2026 Compared to List and U.S. Market Prices","author":"US Department of Health and Human Services","year":"2024","unstructured":"US Department of Health and Human Services: Medicare Drug Price Negotiation Program: Medicare Prices Negotiated for 2026 Compared to List and U.S. Market Prices. Washington, DC, ASPE Issue Brief, 2024"},{"key":"e_1_3_5_36_2","first-page":"432","article-title":"Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028","volume":"23","author":"Miksad R","year":"2026","unstructured":"Miksad R, Sarkar S, Abernethy A, et al: Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028. J Manag Care Spec Pharm 23:432-448, 2026","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00639"},{"key":"e_1_3_5_38_2","volume-title":"FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph (Keytruda Qlex\u2122) for Subcutaneous Injection","year":"2025","unstructured":"FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph (Keytruda Qlex\u2122) for Subcutaneous Injection. FDA News Release. 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-26-00461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:59:15Z","timestamp":1790711955000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-26-00461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":37,"alternative-id":["10.1200\/OP-26-00461"],"URL":"https:\/\/doi.org\/10.1200\/op-26-00461","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"2026-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-26-00461"}}